The Gene Editing Company That Wants to Replace Your Cholesterol Meds
A gene editing startup co-founded by a Nobel laureate just filed to go public, and it's not chasing rare diseases. Scribe Therapeutics wants to use CRISPR to replace your daily cholesterol pills with a single dose that silences the genes behind heart disease.
A Nobel Laureate's Startup Heads to Wall Street
Imagine taking a single treatment and never worrying about your cholesterol again. No daily pills. No monthly injections. Just one dose, and your liver quietly stops making the protein that drives your LDL-C sky high.
That's the pitch from Scribe Therapeutics, a gene editing company co-founded by Nobel laureate Jennifer Doudna. Last week, the company filed its S-1 with the SEC to go public, seeking to raise up to $75 million on the Nasdaq under the ticker SCTX. The proceeds? They're going straight into pushing a new class of cholesterol-lowering medicines through clinical trials.
If that sounds like a strange move for a CRISPR company, you're paying attention. Gene editing has been synonymous with rare diseases, sickle cell, and inherited blindness. Scribe is betting that the biggest opportunity is actually the most common killer in America: heart disease.
Not Your Average CRISPR Company
Most gene editing companies build their drugs around Cas9, the molecular scissors that won Doudna and Emmanuelle Charpentier the Nobel Prize in 2020. Scribe took a different path. The company's platform is built on CasX, a smaller, lesser-known cousin of Cas9 that's been engineered beyond recognition.
How engineered? Scribe's lead enzyme, called XE, sits more than 125 mutations away from the natural CasX protein. Think of it like taking a Honda Civic engine and rebuilding it until you've got a Formula 1 powertrain. The result is an enzyme with over 100 times the gene-editing activity of the original, with no detectable off-target effects in preclinical testing.
But the really clever part isn't the cutting. It's the not cutting.
Scribe's lead drug candidate, STX-1150, uses a technology called ELXR (Epigenetic Long-Term X-Repressor). Instead of snipping your DNA permanently, ELXR parks itself on the PCSK9 gene in your liver cells and slaps a chemical "do not read" sign on it. The gene stays intact; your cells just stop making the PCSK9 protein that raises LDL cholesterol. Think of it as putting a book back on the shelf with a lock on it, rather than tearing out the pages.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This epigenetic approach could matter a lot. Permanent DNA cuts carry risks: unintended mutations, chromosome rearrangements, things you really don't want happening in a treatment designed for millions of otherwise healthy people. Scribe's bet is that silencing without cutting gives them a wider safety margin for a preventive therapy.
The Pipeline: Three Shots at the Lipid Trifecta
Scribe isn't going after just one cholesterol target. The company has laid out a three-program cardiometabolic pipeline, each attacking a different lipid villain.
STX-1150 (PCSK9, LDL cholesterol) is the lead candidate. It's already in a Phase 1 trial in Australia, dosing adults with high LDL-C and elevated heart disease risk. Top-line data on cholesterol lowering are expected in the first half of 2027. In monkeys, a single dose produced roughly 18 months of sustained LDL-C reduction. That's the kind of durability that could make daily statins look like rotary phones.
STX-1200 (LPA, lipoprotein(a)) targets Lp(a), a genetically determined risk factor that affects about 20% of the global population. There's currently no approved drug to lower it. This program is still preclinical, supported by a $25 million-plus grant from the California Institute for Regenerative Medicine.
STX-1400 (APOC3, triglycerides) uses Scribe's XE gene editor (the one that does cut DNA) to knock out APOC3 production in the liver. In preclinical models, it achieved over 95% triglyceride reduction and more than 75% editing efficiency in monkey liver cells, with no detectable off-target edits. This program targets severe conditions like familial chylomicronemia syndrome, where sky-high triglycerides can trigger life-threatening pancreatitis.
Pharma Has Already Written Some Very Large Checks
Scribe isn't showing up to Wall Street empty-handed. The company has three major pharma partnerships that collectively represent billions in potential milestone payments.
Eli Lilly (through its subsidiary Prevail Therapeutics) paid $75 million upfront for exclusive rights to Scribe's gene editing platform for neurological and neuromuscular diseases. That deal includes over $1.5 billion in potential milestones and low-double-digit royalties.
Sanofi has two separate deals with Scribe. The first, signed in 2022, covers NK cell cancer therapies ($25 million upfront, over $1 billion in milestones). The second, from 2023, targets sickle cell disease and other genetic conditions with in vivo editing ($40 million upfront, over $1.2 billion in milestones). Sanofi has already exercised options to expand both collaborations, and Scribe hit its first success milestone in early 2025.
Biogen rounds out the trifecta with a collaboration focused on genetically driven ALS, though financial terms haven't been disclosed.
All told, Scribe has pulled in about $180 million in upfront, milestone, and reimbursement payments from partners, plus roughly $150 million in equity financing from investors like Andreessen Horowitz, RA Capital, and T. Rowe Price.
The Competitive Chessboard
Scribe isn't the only company trying to edit cholesterol out of existence. Verve Therapeutics, now partnered with Eli Lilly, is running the most advanced clinical program in the space. Its PCSK9 base editor, VERVE-102, showed a 62% LDL-C reduction in humans with durability out to 18 months. That's the benchmark Scribe has to beat, or at least match with a better safety profile.
The key differentiator? Verve permanently changes the DNA sequence. Scribe silences the gene without altering a single nucleotide. If regulators and patients end up caring deeply about reversibility (even theoretical reversibility), Scribe's epigenetic approach could have an edge. If all that matters is efficacy, Verve has a head start measured in years.
Why This IPO Matters Beyond Scribe
Scribe would be roughly the 14th biotech IPO of 2026, joining a class that's already raised around $5 billion collectively. That's the strongest showing since 2021's pandemic-era boom.
The quality bar, though, is dramatically higher. Eleven of this year's first 13 biotech IPOs raised at least $250 million each. The market isn't rewarding speculative science anymore; it wants clinical data, pharma validation, and a clear path to value.
Scribe checks several of those boxes: a Nobel-pedigree platform, three blue-chip pharma partners, a Phase 1 trial already dosing patients, and a target market (cardiovascular disease) that dwarfs the rare disease niches where gene editing has lived until now.
The S-1 still has plenty of blanks to fill in: no share price range, no share count, and the company itself flags "substantial doubt about its ability to continue as a going concern" without the IPO capital. That's standard boilerplate for pre-revenue biotechs, but it's a reminder that this is still a bet on the come.
Goldman Sachs, Leerink Partners, Guggenheim Securities, and Wells Fargo are running the book. When those names show up on the cover page, it signals that serious institutional buyers are at least willing to listen.
The question now is whether Wall Street believes a single dose can replace a lifetime of pills. If it does, Scribe's IPO might be the opening act for an entirely new era of cardiovascular medicine.
5 min read
Genentech Cut 103 Jobs and Wrote a $490M Check on the Same Day
Genentech axed 103 scientists from its storied research unit and signed a $490 million breast cancer deal with Astex on virtually the same timeline. It's the clearest signal yet of how big pharma is reshuffling the R&D deck in 2026.
